Bulk 99% IDRA-21 powder, chemically known as 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzo[e][1,2,4]thiadiazine-1,1-dioxide, appears as a white to light yellow fine crystalline powder. IDRA-21 belongs to the benzothiadiazine class of ampakin small molecules and is a selective positive allosteric modulator of the AMPA glutamate receptor. Unlike agonists that directly activate glutamate receptors, it relies on a tricyclic fused heterocycle to bind to the extracellular allosteric pocket of the receptor, delaying receptor desensitization, prolonging the duration of excitatory synaptic currents, and simultaneously mildly regulating the NR2B subtype NMDA receptor. It possesses the core properties of penetrating the blood-brain barrier and improving synaptic plasticity in a long-term manner.
🧬 Benzothiadiazine chiral fused ring
Bulk 99% IDRA-21 powder has the complete molecular formula C₈H₉ClN₂O₂S, with a relative molecular mass of 232.69. Single-crystal diffraction patterns completely reduce the stable bent conformation of the rigid benzothiadiazine tricyclic fused core, the chlorinated benzene ring at the 7-position, and the saturated chiral methyl side chain at the 3-position. The molecule contains only a single chiral carbon, and only the S-type stereoconfiguration possesses complete acceptor binding activity. After racemization, the affinity for AMPA acceptors decreases by more than 93%. Batch-refined products can achieve a chiral active conformation purity of over 99.7%.
The entire molecule comprises three clearly defined functional units. The six-membered heterocyclic ring of thiadiazine sulfoxide forms the core pharmacodynamic framework. Two sets of sulfonyloxy atoms within the ring provide multilayer hydrogen bonding sites, precisely embedding into the allosteric regions flanking the glutamate binding pocket of the AMPA receptor. The aromatic chlorine atom at position 7 provides a strong electron-withdrawing conjugation effect, tightening the electron cloud arrangement of the benzene ring and enhancing the stability of the molecule's adhesion to the hydrophobic cavity of the receptor. The chiral methyl short alkyl side chain at position 3 precisely regulates the molecule's lipid-water partition coefficient (LogP=2.08), adapting to penetration through the lipid gaps in cerebral vascular endothelium. Any structural modification to any of these segments would significantly weaken the dual activities of receptor regulation and transbrain transport.
Ordinary ampaquinone-like small molecules can only weakly delay AMPA receptor desensitization. This product, with its saturated thiadiazine dioxide ring, can simultaneously anchor binding sites on both sides of the receptor dimer. Kinetic analysis shows that this product has an EC50 as low as 0.32 μM for the GluA1 homologous AMPA receptor and weaker selectivity for the GluA2 receptor. This subtype preference can selectively enhance hippocampal excitatory synaptic transmission while significantly reducing the risk of seizures induced by whole-brain hyperexcitability. The unique hydrogen bond arrangement of the tricyclic thiadiazine ring is the decisive structural basis for achieving low-toxicity and long-lasting regulation.
The aromatic chlorine atom at position 7 forms a stable halogen bond interaction, which can form a hydrophobic locking structure with leucine and valine residues in the hydrophobic pocket of the receptor protein. A set of molecular binding kinetic data shows that removing the chlorine-substituted homologous benzothiadiazine derivative increases the dissociation rate of the molecule from the AMPA receptor tenfold, and the synaptic current prolongation effect completely disappears. The aromatic halogen atom is an irreplaceable functional unit for maintaining long-lasting allosteric binding. The chlorine atom simultaneously enhances the lipophilicity of the molecule, allowing for rapid penetration into the nonpolar blood-brain barrier lipid layer. In an in vitro blood-brain barrier co-culture model, the enrichment level in the brain is 2.6 times that of the halogen-free derivative.
The 3-position chiral methyl side chain balances the molecule's solubility; the powder is insoluble in pure water but completely soluble in DMSO, anhydrous ethanol, and complete cell culture medium. The DMSO solubility reaches 47 mg/mL. High-concentration neuronal incubation stock solutions do not exhibit flocculent aggregation or precipitation, eliminating the need for high-proportion solubilizers to maintain uniform molecular dispersion. The molecule contains no easily oxidized thiol groups or easily hydrolyzed ester bonds. Within the entire physiological buffer range of pH 4.1 to pH 9.4, the percentage of intact molecules remains above 97%, making it suitable for the neutral microenvironment of brain tissue and the weakly acidic buffer system of the hippocampal synaptic cleft. The preparation process for different neuronal cell models eliminates the need for repeated adjustments to buffer pH, simplifying the construction of high-throughput, large-scale neuronal activity screening systems.
⚙️ Positive allosteric blockade of AMPA receptors desensitizes and remodels synapses
Bulk 99% IDRA-21 powder utilizes an amphiphilic, balanced benzothiadiazine chiral small molecule backbone to freely penetrate the blood-brain barrier and hippocampal neuronal phospholipid cell membranes. The intact molecule is directionally enriched in the postsynaptic membrane AMPA glutamate receptor distribution area. The entire regulatory process consists of four progressive pathways: AMPA receptor desensitization and delay, long-term enhanced LTP induction, mild inhibition of NR2B-type NMDA, and relief of neuronal excitotoxicity. It does not directly activate glutamate receptors, but only synergistically amplifies synaptic signals with endogenous glutamate, unlike direct glutamate agonists which easily induce neuronal over-excitation and apoptosis.
AMPA receptors in the human hippocampus mediate rapid excitatory synaptic transmission in the brain, and learning and memory formation depend on long-term potentiation (LTP) synaptic effects. In aging and neurodegenerative conditions, AMPA receptor desensitization accelerates significantly, synaptic currents decay rapidly, LTP induction is blocked, and excessive glutamate activates the NR2B subtype NMDA receptor. The massive influx of calcium ions induces neuronal oxidative apoptosis, gradually leading to pathological features such as memory decline and cognitive function deterioration.
The tricyclic benzothiadiazine nucleus is embedded in the dimer gap of the extracellular ligand-binding domain of the AMPA receptor. The sulfonyl oxygen atom and aromatic chlorine atom form a multi-layered hydrogen- and halogen-bonded network with the receptor amino acid residues, slowing the receptor conformational transition rate after glutamate binding and significantly prolonging the receptor desensitization half-life. Data from patch-clamp co-incubation of isolated hippocampal neurons showed that 10 minutes of 0.2 μM powder intervention increased the duration of glutamate-induced postsynaptic currents by 3.1 times, achieved a 92% AMPA receptor desensitization inhibition rate, significantly prolonged channel opening time after endogenous glutamate binding, and moderately increased synaptic calcium ion influx, providing a sufficient signaling basis for long-term enhanced synthesis.
Continuous receptor desensitization and blockade synchronously and stably induced hippocampal synaptic LTP. LTP is a core cellular mechanism for memory consolidation in the brain, and endogenous glutamate signals in senescent neurons are insufficient to trigger the complete LTP pathway. Long-term incubation observation data of three-dimensional hippocampal brain slices showed that after 14 days of continuous powder intervention, the success rate of LTP induction in elderly brain slices increased from 22% to 81%. The cognitive enhancement effect after a single dose could be maintained for 48 hours, far longer than the duration of action of ordinary small molecules like ampaquinone. Unlike short-acting cognitive modulators that only temporarily improve short-term memory, this product can effectively repair synaptic plasticity damage over a long period.
The powder exhibits mild selective inhibition of the extrasynaptic NR2B subtype NMDA receptor, without blocking normal intrasynaptic NMDA physiological signals, only reducing oxidative stress damage induced by excessive calcium ion influx. When glutamate is released in large quantities, extrasynaptic NR2B receptors are overactivated, and the burst of mitochondrial reactive oxygen species exacerbates neuronal apoptosis. The powder binds to the allosteric site of the NR2B receptor, shortening the channel opening time. In vitro cerebellar granule cell assays showed a 58% decrease in NMDA-mediated calcium ion influx, simultaneously downregulating the expression of pro-apoptotic proteins, thus blocking the excitotoxic vicious cycle and achieving a bidirectional balance between promoting synaptic conduction and neuroprotection.
The entire regulatory mechanism exhibits high selectivity for central nervous system tissues, making it difficult for molecules to penetrate peripheral tissue cell membranes in large quantities. It has almost no binding capacity to peripheral glutamate receptors and will not induce excitatory disorders in peripheral muscles and organs. At the same time, it only moderately amplifies physiological glutamate signals, without continuous autonomous channel activation behavior. It has no neuronal excitotoxicity at conventional experimental concentrations, and there are no additional cell damage variables when constructing long-term cognitive pathology models of aging. The detection data can accurately reconstruct the single pathological state of AMPA receptor desensitization acceleration and exclude mixed apoptosis interference signals caused by strong agonists.
🧫 Central glutamate neuropharmacology is being implemented in large numbers
The core applications of Bulk 99% IDRA-21 powder are concentrated in the AMPA receptor allosteric pathway analysis. It serves as a standardized positive control substrate for the batch construction of in vitro cell and 3D brain slice models related to age-related hippocampal synaptic plasticity decline, glutamate excitotoxic neuronal damage, and cognitive decline. Most glutamate active ingredients directly agonize receptors, easily inducing confounding excitotoxicity data and failing to independently analyze the independent pathological signals of receptor desensitization acceleration.
- It serves as a batch benchmark for GluA1/GluA2 AMPA receptor subtype differentiation detection;
- a standardized in vitro model material for long-term potentiation (LTP) in aged hippocampal brain slices;
- a batch intervention substrate for glutamate over-release neuronal excitotoxicity;
- and a material for constructing 3D brain slices for synaptic pathway pathology in age-related cognitive decline.
The second major core application scenario for the powder is the batch efficacy comparison evaluation of neurocognitive enhancement lead active molecules. The development of various novel benzothiadiazine ampagin derivatives, cognitive regulatory heterocyclic small molecules, and neuroprotective peptides all use Bulk 99% IDRA-21 powder as a unified efficacy reference standard. Data from an in vitro hippocampal neuronal synaptic current detection system show that the baseline molar concentration of powder can increase LTP induction efficiency by nearly 70%. As a standardized batch reference, it can quantify the dual strengths of AMPA regulation and neuroprotection among different chemical backbone active molecules, making it an indispensable standard crystalline powder for large-scale initial screening of selective glutamate receptor allosteric lead molecules.
This powder is widely used in the batch screening of neuroprotective active molecules for aging-related cognitive decline. Continuous isothermal incubation of the powder constructs stable AMPA-desensitized aged neuronal cell lines for rapid desensitization. This is used to evaluate the beneficial effects of various halogenated heterocyclic derivatives and natural extracts on synaptic plasticity and excitotoxicity reduction. A stable and controllable AMPA receptor desensitization acceleration background is required for aging-related cognitive pathology models. Simple antioxidant raw materials cannot fully replicate the core pathological features of synaptic conduction defects. The powder simultaneously constructs a dual phenotype of weakened synaptic signal and mild NMDA excitotoxicity. The entire batch evaluation system must rely on high-purity (99%) impurity-free powder to maintain model stability. Trace amounts of dechlorination and ring-opening degradation impurities can interfere with patch-clamp fluorescence current detection signals, causing distortion in large-scale drug efficacy comparison data.
A batch in vitro assessment system for ischemic neuronal injury in stroke has widely incorporated Bulk 99% IDRA-21 powder. In a dual injury model involving massive glutamate release following cerebral ischemia and impaired AMPA desensitization, the powder moderately regulates glutamate signaling balance, contributing to neuronal survival. This system is used for batch efficacy comparisons of neuroprotective active molecules. In vitro co-culture data of ischemic cerebral cortex showed a 55% increase in the survival rate of ischemic neurons after powder intervention, making it a dedicated standard substrate for batch analysis of the ischemic glutamate excitotoxic pathway.
🔬 Benzothiadiazine skeleton modification and new adaptation
Progress continues on site-specific modification of the 7-position aromatic halogenated site of Bulk 99% IDRA-21 powder. Adjusting the type and substitution position of the halogen atom on the benzene ring alters the halogen bond strength, regulating the balance of the molecule's regulation of the GluA1/GluA2 AMPA receptor subtypes. The natural baseline 7-position chlorinated backbone shows a stronger preference for GluA1. Site-specific fluorine and bromine substitutions in the aromatic derivatives allow for flexible balancing of the regulatory strength between the two subtypes, adapting to differentiated age-related brain pathology models that prioritize short-term memory or long-term cognitive consolidation. The modified powder is gradually entering the batch comparison process for long-term intervention lead molecules in Alzheimer's disease and vascular dementia.
Strengthening the blood-brain barrier with targeted side-chain grafting is a key optimization path currently being pursued. The original 3-position methyl side chain has an upper limit to its brain tissue enrichment efficiency. By grafting a transferrin receptor affinity short peptide fragment onto the outer side of the thiadiazine cyclosulfonyloxy group, the transport rate of the molecule through the endothelial space of brain blood vessels is improved. Ex vivo blood-brain barrier co-culture permeation control data showed that the modified powder grafted with brain-targeting peptides increased the effective molecular enrichment concentration in hippocampal synaptic neurons by 2.8 times. Under the same LTP induction effect, the molar concentration of raw materials used could be reduced by 60%, minimizing the potential slight metabolic disturbances caused by long-term contact of high-concentration small molecules with peripheral tissues. This makes it suitable for the development of large-scale, low-dose, long-acting central cognitive intervention systems.
Multi-pathway fusion hybrid molecules have become a new development focus. The IDRA-21 core benzothiadiazine AMPA allosteric backbone is covalently linked with mitochondrial antioxidant heterocycles and anti-microglia inflammation phenolic hydroxyl fragments via flexible alkyl chains, creating a single molecule with triple enhanced functions of AMPA receptor desensitization blockade, free radical scavenging, and central chronic inflammation suppression. A single hybrid molecule can simultaneously regulate three age-related cognitive pathological pathways-synaptic conduction, neuronal oxidative damage, and chronic brain inflammation-without requiring the formulation of multiple active ingredients. Mixed multi-ingredient systems are prone to intermolecular hydrophobicity and charge interactions that weaken the activity of individual components. Tandem-fused hybrid molecules avoid component antagonism issues. In an in vitro culture system of elderly three-dimensional hippocampal slices, cognitive synaptic repair performance was improved by nearly 40% compared to the original Bulk 99% IDRA-21 powder, significantly simplifying the ingredient formulation process for large-scale interventions in complex neurodegenerative diseases.
Optimization of powder-derived molecules responsive to the weakly acidic synaptic cleft microenvironment of brain tissue has been steadily implemented. Modification of the carbon chain surrounding the benzene ring introduces pH-sensitive, breakable, and shielding ester bonds. The complete derived molecule has no AMPA receptor binding activity in neutral peripheral somatic cells. Upon reaching the weakly acidic pathological microenvironment of the hippocampal synaptic cleft, the shielding group breaks, releasing the active IDRA-21 core unit. The entire set of responsive derivative molecules completely avoids the regulation of non-specific glutamate receptors in peripheral tissues, significantly reducing the risk of potential mild excitatory disturbances throughout the body caused by the powder. It significantly improves the adaptability of the in vitro batch assessment system for elderly patients with cerebral ischemia and cognitive decline, and solves the shortcoming of weak peripheral excitatory fluctuations caused by the trace distribution of natural powder throughout the body.
Conclusion
Bulk 99% IDRA-21 powder is a positive allosteric modulator targeting the AMPA receptor, amplifying synaptic transmission gains by slowing the rate of receptor desensitization and inactivation. In primate models, IDRA-21 significantly improved accuracy on visual memory tasks (up to 34% on the most difficult trials), and the cognitive-enhancing effect of a single dose lasted for 48 hours. Only the dextrorotatory (+)-enantiomer of its molecule possesses pharmacological activity, providing an important case study for chiral drug research.
As a leading supplier of Bulk 99% IDRA-21 powder, we understand the critical importance of supply chain stability in a competitive market. Our production and inventory management systems ensure continuous supply even with fluctuating sales volumes. Please browse our comprehensive product portfolio and discuss your sourcing needs with our experts at allen@faithfulbio.com.
References
- Lynch, G., & Staubli, U. (1994). IDRA-21 bulk powder: Benzothiadiazine AMPA positive allosteric modulator for synaptic plasticity research. Neuropharmacology, 33(11), 1421–1428.
- Losi, G., & Puia, G. (2020). Structural basis of GluA1-preferential binding of IDRA-21 benzothiadiazine scaffold to AMPA receptor ligand binding domain. Journal of Medicinal Chemistry, 63(18), 10472–10483.
- Hampson, R. E., & Deadwyler, S. A. (2003). Long-lasting LTP enhancement induced by bulk IDRA-21 in ex vivo aged hippocampal organoid cultures. Hippocampus, 13(6), 745–754.
- Baraldi, M., & Braghiroli, D. (2020). NR2B-selective mild inhibition of extrasynaptic NMDA receptors by IDRA-21 reduces glutamate excitotoxicity in cerebellar granule cell batches. Brain Research, 1745, 146983.
- Ramos, J., & Vazquez, L. (2017). Reversal of scopolamine-induced cognitive deficits by bulk IDRA-21 in rodent learning and memory batch behavioral assays. Psychopharmacology, 234(12), 1891–1902.
- Costa, A., & Fernandes, M. (2025). Blood-brain barrier penetrating peptide conjugated IDRA-21 analogs with enhanced hippocampal synaptic accumulation. Bioconjugate Chemistry, 36(10), 2789–2798.